Cessation and resuming of alglucosidase alfa in Pompe disease: a retrospective analysis

Journal of Neurology

Volumn 261, Issue 9, 2014, Pages 1684-1690

  Hundsberger, Thomas ^a   Rösler, Kai M ^b   Findling, Oliver ^b  

^a CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

Enzyme replacement therapy; GSD II; Metabolic disease; Muscle disease; Pompe disease

Indexed keywords

ALPHA GLUCOSIDASE;

ADULT; ADVERSE EFFECTS; BREATHING; ENZYME REPLACEMENT; FEMALE; GLYCOGEN STORAGE DISEASE TYPE II; HUMAN; MALE; MIDDLE AGED; MUSCLE STRENGTH; PATHOPHYSIOLOGY; PROCEDURES; RETROSPECTIVE STUDY; SWITZERLAND; TIME; TREATMENT OUTCOME; VITAL CAPACITY; WALKING;

ADULT; ALPHA-GLUCOSIDASES; ENZYME REPLACEMENT THERAPY; FEMALE; GLYCOGEN STORAGE DISEASE TYPE II; HUMANS; MALE; MIDDLE AGED; MUSCLE STRENGTH; RESPIRATION; RETROSPECTIVE STUDIES; SWITZERLAND; TIME FACTORS; TREATMENT OUTCOME; VITAL CAPACITY; WALKING;

EID: 84939876357     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-014-7402-z     Document Type: Article

References (25)

1. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories (2002) ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 166:111–117
2. Angelini C, Semplicini C, Ravaglia S, Bembi B, Servidei S, Pegoraro E, Moggio M, Filosto M, Sette E, Crescimanno G, Tonin P, Parini R, Morandi L, Marrosu G, Greco G, Musumeci O, Di IG, Siciliano G, Donati MA, Carubbi F, Ermani M, Mongini T, Toscano A (2012) Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4 years. J Neurol 259:952–958
3. Bembi B, Cerini E, Danesino C, Donati MA, Gasperini S, Morandi L, Musumeci O, Parenti G, Ravaglia S, Seidita F, Toscano A, Vianello A (2008) Management and treatment of glycogenosis type II. Neurology 71:S12–S36
4. Bembi B, Pisa FE, Confalonieri M, Ciana G, Fiumara A, Parini R, Rigoldi M, Moglia A, Costa A, Carlucci A, Danesino C, Pittis MG, Dardis A, Ravaglia S (2010) Long-term observational, non-randomized study of enzyme replacement therapy in late-onset glycogenosis type II. J Inherit Metab Dis 33:727–735
5. Chetta A, Zanini A, Pisi G, Aiello M, Tzani P, Neri M, Olivieri D (2006) Reference values for the 6-min walk test in healthy subjects 20–50 years old. Respir Med 100:1573–1578
6. de Vries JM, van der Beek NA, Hop WC, Karstens FP, Wokke JH, de Visser M, van Engelen BG, Kuks JB, van der Kooi AJ, Notermans NC, Faber CG, Verschuuren JJ, Kruijshaar ME, Reuser AJ, van Doorn PA, van der Ploeg AT (2012) Effect of enzyme therapy and prognostic factors in 69 adults with Pompe disease: an open-label single-center study. Orphanet J Rare Dis 7:73
7. Hundsberger T, Rohrbach M, Kern L, Rosler KM (2013) Swiss national guideline for reimbursement of enzyme replacement therapy in late-onset Pompe disease. J Neurol 260:2279–2285
8. Jurecka A, Zuberuber Z, Opoka-Winiarska V, Wegrzyn G, Tylki-Szymanska A (2012) Effect of rapid cessation of enzyme replacement therapy: a report of 5 cases and a review of the literature. Mol Genet Metab 107:508–512
9. Kishnani PS, Corzo D, Nicolino M, Byrne B, Mandel H, Hwu WL, Leslie N, Levine J, Spencer C, McDonald M, Li J, Dumontier J, Halberthal M, Chien YH, Hopkin R, Vijayaraghavan S, Gruskin D, Bartholomew D, van der Ploeg A, Clancy JP, Parini R, Morin G, Beck M, De la Gastine GS, Jokic M, Thurberg B, Richards S, Bali D, Davison M, Worden MA, Chen YT, Wraith JE (2007) Recombinant human acid a-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 68:99–109
10. Kroos M, Hoogeveen-Westerveld M, van der Ploeg A, Reuser AJ (2012) The genotype-phenotype correlation in Pompe disease. Am J Med Genet C Semin Med Genet 160C:59–68
11. Lachmann R, Schoser B (2013) The clinical relevance of outcomes used in late-onset Pompe disease: can we do better? Orphanet J Rare Dis 8:160–172
12. Laloui K, Wary C, Carlier RY, Hogrel JY, Caillaud C, Laforet P (2011) Making diagnosis of Pompe disease at a presymptomatic stage: to treat or not to treat? Neurology 77:594–595
13. Lin DS, Chiang MF, Ho CS, Hsiao CD, Lin CY, Wang NL, Chuang CK, Huang YW, Chang PC, Liu HL (2013) Low-frequency enzyme replacement therapy in late-onset Pompe disease. Muscle Nerve 47:612–613
14. Raben N, Wong A, Ralston E, Myerowitz R (2012) Autophagy and mitochondria in Pompe disease: nothing is so new as what has long been forgotten. Am J Med Genet C Semin Med Genet 160:13–21
15. Regnery C, Kornblum C, Hanisch F, Vielhaber S, Strigl-Pill N, Grunert B, Muller-Felber W, Glocker FX, Spranger M, Deschauer M (2012) 36 months observational clinical study of 38 adult Pompe disease patients under alglucosidase alfa enzyme replacement therapy. J Inherit Metab Dis 35:837–845
16. Schoser B, Hill V, Raben N (2008) Therapeutic approaches in glycogen storage disease type II/Pompe disease. Neurotherapeutics 5:569–578
17. Simoens S, Cassiman D, Dooms M, Picavet E (2012) Orphan drugs for rare diseases: is it time to revisit their special market access status? Drugs 72:1437–1443
18. Strothotte S, Strigl-Pill N, Grunert B, Kornblum C, Eger K, Wessig C, Deschauer M, Breunig F, Glocker FX, Vielhaber S, Brejova A, Hilz M, Reiners K, Muller-Felber W, Mengel E, Spranger M, Schoser B (2010) Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial. J Neurol 257:91–97
19. Thurberg BL, Lynch MC, Vaccaro C, Afonso K, Tsai AC, Bossen E, Kishnani PS, O’Callaghan M (2006) Characterization of pre- and post-treatment pathology after enzyme replacement therapy for Pompe disease. Lab Invest 86:1208–1220
20. Toscano A, Schoser B (2013) Enzyme replacement therapy in late-onset Pompe disease: a systematic literature review. J Neurol 260:951–959
21. van den Hout JM, Kamphoven JH, Winkel LP, Arts WF, De Klerk JB, Loonen MC, Vulto AG, Cromme-Dijkhuis A, Weisglas-Kuperus N, Hop W, Van HH, van Diggelen OP, Boer M, Kroos MA, van Doorn PA, Van der Voort E, Sibbles B, Van Corven EJ, Brakenhoff JP, Van Hove J, Smeitink JA, de Jong G, Reuser AJ, van der Ploeg AT (2004) Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. Pediatrics 113:e448–e457
22. van der Beek NA, de Vries JM, Hagemans ML, Hop WC, Kroos MA, Wokke JH, de Visse M, van Engelen BG, Kuks JB, van der Kooi AJ, Notermans NC, Faber KG, Verschuuren JJ, Reuser AJ, van der Ploeg AT, van Doorn PA (2012) Clinical features and predictors for disease natural progression in adults with Pompe disease: a nationwide prospective observational study. Orphanet J Rare Dis 7:88
23. van der Beek NA, Hagemans ML, Reuser AJ, Hop WC, van der Ploeg AT, van Doorn PA, Wokke JH (2009) Rate of disease progression during long-term follow-up of patients with late-onset Pompe disease. Neuromuscul Disord 19:113–117
24. van der Ploeg AT, Clemens PR, Corzo D, Escolar DM, Florence J, Groeneveld GJ, Herson S, Kishnani PS, Laforet P, Lake SL, Lange DJ, Leshner RT, Mayhew JE, Morgan C, Nozaki K, Park DJ, Pestronk A, Rosenbloom B, Skrinar A, van Capelle CI, van der Beek NA, Wasserstein M, Zivkovic SA (2010) A randomized study of alglucosidase alfa in late-onset Pompe’s disease. N Engl J Med 362:1396–1406
25. van der Ploeg AT, Reuser AJ (2008) Pompe’s disease. Lancet 372:1342–1353